10/2025
Vaccentis goes Vienna – New EU Hub opens in the Seestadt biotech cluster! We are…
10/2025
Vaccentis is pleased to announce the signing of a letter of intent for a strategic…
09/2025
It offered a great chance for Vaccentis President of the Board Matthias Oertle, CEO Martin…
09/2025
It was a great opportunity for Vaccentis CEO Martin Munte and Head of R&D and…
07/2025
We are delighted to announce that Patrik Grandits has joined the Vaccentis AG Board of Directors! With…
06/2025
On June 17th we held our Annual General Meeting in Zürich. We presented our strategic…
06/2025
The Vaccentis roadshow with 8 Hours Ahead in Hong Kong and China in May 2025…
05/2025
Vaccentis is very pleased to announce the collaboration with Krems Bioanalytics! Together with our Head…
05/2025
It was a great opportunity for Vaccentis to present the company's focus areas in the…
04/2025
Great Vaccentis video recording with Reinhard Rosenberger and his team, with our Head of Research…
04/2025
Vaccentis CEO Martin Munte acknowledges the potential of a R&D hub in Vienna in oe24…
02/2025
Cancer vaccine from Austria: “Approval by 2029 realistic” Link: Krebsimpfstoff aus Österreich: "Zulassung bis 2029…
02/2025
Science that gives hope. New cancer treatment options are presented on World Cancer Day in…
01/2025
Our Head of R&D and CMO Ingrid Rauter met with Krems Bioanalytics to discuss key R&D projects for the…
01/2025
After a long time of research in the field of oncology immunotherapy major breakthrough developments…
